Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Texas is one of a handful of states nationwide that require attorneys to disclose their use of artificial intelligence in court filings. And some attorneys are being required to take continuing legal ...

What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...

Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

US pharma major Eli Lilly is raising the list price for its obesity drug Mounjaro (tirzepatide) in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.